Search
Login
Register
Menu
Last issue
Home
News
CongressUpdate
Specials
Guidelines
Links
All
All
BJMO articles
Blog articles
Specials
Search
Forgot Password?
Not a member yet? Register here
Journal issues
>
Immunotherapy Special, December 2024
Immunotherapy Special, December 2024
Immunotherapy Special, December 2024
Previous issue
Next issue
All issues
Subscribe
Quickly to
REVIEW ONCOLOGY
PRACTICE GUIDELINES
PHARMACOTHERAPY
RESEARCH
ONCOCASE
ONCOTHESIS
CONGRESS NEWS
REIMBURSEMENT NEWS
Index
SPECIAL
Long-term data solidify nivolumab + cabozantinib as a standard first line treatment for patients with advanced renal cell carcinoma
T. Feys, J. Blokken
Immunotherapy: a new standard first-line treatment for patients with advanced dMMR/MSI-H endometrial cancer
T. Feys
To resect or not to resect: Immunotherapy options for NSCLC
J. Collins
Tumour-agnostic therapies in oncology: a big leap towards true treatment personalisation
T. Feys
PHARMA NEWS
Real-world evidence with durvalumab after chemoradiotherapy in patients with unresectable NSCLC
Cabozantinib – efficacy and safety across cancer types
Top
